What question did this study set out to answer?

This research examines how CDK4/6 inhibitors, like PD0332991, can replace the functions of p21 and p16 in initiating senescence.

September 15, 2013Cell CycleOpen Access

CDK4/6-inhibiting drug substitutes for p21 and p16 in senescence: Duration of cell cycle arrest and MTOR activity determine geroconversion

View Full Paper

Ask AI

Bookmark

Authors

Randomized trial explores how CDK4/6 inhibitors affect senescence and geroconversion, indicating a new therapeutic avenue.

This research examines how CDK4/6 inhibitors, like PD0332991, can replace the functions of p21 and p16 in initiating senescence.
Investigated the influence of CDK4/6 inhibitor PD0332991 on senescence markers in cell cultures.
Analyzed the relationship between cell cycle arrest and MTOR activity in driving senescence.
Compared the effects of p21 and p16 with PD0332991 regarding senescence induction.
PD0332991 induced cyclin D1-positive senescence similar to p21 and p16, confirming their roles in cell cycle arrest.
All three molecules (p21, p16, PD0332991) did not inhibit MTOR, allowing for continued activity, which is crucial for geroconversion.
Rapamycin effectively slowed down the geroconversion initiated by p21, p16, and PD0332991.

Leontieva et al. (2013) studied this question.

View Full Paper

Ask AI

Bookmark